The Numbers Don't Lie: Erik Haines of QSight on the Future of Aesthetics at Octane 2025

In this episode of Plastic Surgery Untold, we're diving into the power of data in aesthetics with special guest Erik Haines from QSight, recorded live at the Aesthetics Tech Forum by Octane. QSight is transforming the industry by providing real-time insights into trends, patient behaviors, and market shifts—helping practices optimize their approach and better serve their patients. Key Topics Discussed: The GLP-1 Boom – In 2024, 40% of patients on GLP-1 weight loss medications were new to the aesthetic practice they visited, highlighting the growing crossover between weight loss and aesthetics. The Expansion of GLP-1 Treatments – While medspas now offer GLP-1 treatments, only 40% of plastic surgeons have adopted them, reflecting a more measured approach in incorporating weight loss into aesthetic medicine. A Shift in Spending – Weight loss now accounts for 11% of non-surgical aesthetic revenue in the U.S., a massive increase from just a few years ago, making it one of the fastest-growing categories since Botox revolutionized the industry. Data-Driven Patient Education – With new patients entering aesthetics through weight loss treatments, it's more important than ever to educate them on the full range of aesthetic services and tailor messaging to their unique needs. The aesthetics industry is evolving fast, and data is key to staying ahead of the curve. Tune in to hear expert insights on how real-time analytics are shaping the future of plastic surgery and medspas.